Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A phase II study of axitinib in advanced neuroendocrine tumors
Jonathan Strosberg, Mauro Cives, Justin H. Hwang, et al.
Endocrine Related Cancer (2016) Vol. 23, Iss. 5, pp. 411-418
Open Access | Times Cited: 49

Showing 26-50 of 49 citing articles:

Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy
Judy S. Crabtree
Frontiers in Endocrinology (2017) Vol. 8
Open Access | Times Cited: 14
Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)
Krystallenia Alexandraki, Kosmas Daskalakis, Marina Tsoli, et al.
Trends in Endocrinology and Metabolism (2019) Vol. 31, Iss. 3, pp. 239-255
Closed Access | Times Cited: 13
Drug Development in Neuroendocrine Tumors: What Is on the Horizon?
Alejandro García‐Álvarez, Jorge Hernando Cubero, Jaume Capdevila
Current Treatment Options in Oncology (2021) Vol. 22, Iss. 5
Open Access | Times Cited: 10
Tyrosine kinase inhibitors in patients with neuroendocrine neoplasms: a systematic literature review
Rodrigo G. Taboada, Felícia P. Cavalher, Juliana F. Rego, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 1
Medical Treatment of Gastrointestinal Neuroendocrine Neoplasms
Marina Tsoli, Krystallenia Alexandraki, Christos Xanthopoulos, et al.
Hormone and Metabolic Research (2020) Vol. 52, Iss. 08, pp. 614-620
Open Access | Times Cited: 10
Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications
E Lauricella, Barbara Mandriani, Federica Cavallo, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 6
Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study
Alessandra Dicitore, Germano Gaudenzi, Silvia Carra, et al.
Cancers (2023) Vol. 15, Iss. 22, pp. 5375-5375
Open Access | Times Cited: 3
Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms
Namrata Vijayvergia, Arvind Dasari
Current Treatment Options in Oncology (2020) Vol. 21, Iss. 12
Open Access | Times Cited: 8
Medical Management of Gastroenteropancreatic Neuroendocrine Tumors
Chandrikha Chandrasekharan
Surgical Oncology Clinics of North America (2020) Vol. 29, Iss. 2, pp. 293-316
Open Access | Times Cited: 7
Neuroendocrine neoplasms: Evolving and future treatments
Ariadni Spyroglou, Konstantinos Bramis, Krystallenia Alexandraki
Current Opinion in Endocrine and Metabolic Research (2021) Vol. 19, pp. 15-21
Closed Access | Times Cited: 6
Advances in medical treatment for pancreatic neuroendocrine neoplasms
Yuanliang Li, Zixuan Cheng, Fuhuan Yu, et al.
World Journal of Gastroenterology (2022) Vol. 28, Iss. 20, pp. 2163-2175
Open Access | Times Cited: 4
Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers
Nadia Saoudi, Florian Castet, Elena Élez, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 4
Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms
Chiara Alessandra Cella, Riccardo Cazzoli, Nicola Fazio, et al.
Endocrine Related Cancer (2023) Vol. 30, Iss. 12
Open Access | Times Cited: 2
Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors
Hiroshi Imaoka, Mitsuhito Sasaki, Hideaki Takahashi, et al.
The Oncologist (2018) Vol. 24, Iss. 1, pp. 47-53
Open Access | Times Cited: 5
Treatment strategies for neuroendocrine liver metastases: an update
Diamantis I. Tsilimigras, Malcolm H. Squires, Jordan M. Cloyd, et al.
Expert Opinion on Orphan Drugs (2019) Vol. 7, Iss. 7-8, pp. 327-335
Closed Access | Times Cited: 4
Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor
Florian Bösch, A. Altendorf-Hofmann, Sven Jacob, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 10, pp. 3368-3368
Open Access | Times Cited: 4
Exploring the multifaceted antitumor activity of axitinib in lung carcinoids
Monica Oldani, Maria Celeste Cantone, Germano Gaudenzi, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access
Targeted Therapies
Marianne Pavel, Şuayib Yalçın, Şahin Laçin
Springer eBooks (2024), pp. 645-663
Closed Access
Diagnosis and Management of Parathyroid Carcinoma
Alexander Lazzaro, G Zhao, Matthew H. Kulke
Clinical Pharmacology & Therapeutics (2024)
Closed Access
Solvates and Polymorphs of Axitinib: Characterization and Phase Transformation
Yinhu Pan, Xiao Tong, Yan Wang, et al.
Molecules (2024) Vol. 29, Iss. 19, pp. 4696-4696
Open Access
Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues
Parul Agarwal, Amr Mohamed
Current Treatment Options in Oncology (2022) Vol. 23, Iss. 9, pp. 1233-1246
Closed Access | Times Cited: 2
Data from Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study
Edwin P. Hui, B. Y. Brigette, Herbert H. Loong, et al.
(2023)
Open Access
Advances in Targeted Therapy for Patients with Neuroendocrine Tumours
Vatsala Katiyar, Satya Das
touchREVIEWS in Oncology & Haematology (2022) Vol. 18, Iss. 1, pp. 66-66
Open Access
New Approaches in Medical Therapies
Manila Rubino, Francesca Spada, Alice Laffi, et al.
Springer eBooks (2021), pp. 129-136
Closed Access
Previous Page - Page 2

Scroll to top